30 vehicle M Ruxolitinib the histomorphology of the institutions concerned were standardized on chemistry and lymphopenia were not detected. More than 90% of treated Mice Ruxolitinib survived, whilE by the 22th Day of treatment died more than 90% of Mice treated with vehicle. Pharmacokinetics and metabolism pharmacokinetics and metabolism were Ruxolitinib in early studies in healthy volunteers U single doses of 25 or more mg67 or increasing doses of 5 mg rebuilt as much as 200 mg.68 is 0.95% after an oral dose of the drug is absorbed, and.97% of absorbed SKI-606 Bosutinib drug to plasma proteins bound. The maximum plasma concentration 13 hours after the administration of monophasic or biphasic decline. The terminal half-life betr Gt 2 to 3 hours. The administration of doses up to 200 mg showed a dose-proportional exposure. Ruxolitinib is Haupts Chlich excreted primarily by the liver as a substrate of cytochrome P450 3A4 and its metabolites are in urine.67, 68 There is no evidence of accumulation or Ruxolitinib or its metabolites. K 67 factors that affect the pharmacokinetics of Ruxolitinib Can evaluated. A high fat meal decreased the maximum plasma concentration by 24%, but do not have a significant impact on bioavailability.68 because of the M Opportunities CX-5461 where Ruxolitinib, the exposure of patients can be obtained Ht renal or function liver function .69, observed 70 If co-administration with rifampicin, erythromycin, or no Ruxolitinib change in pharmacokinetics in healthy subjects.71, however, were in healthy volunteers, the u fa re it simultaneously increased with ketoconazole Ruxolitinib hte the AUC by 91% and the half-time of 3.7 to 6.0 hours erh ht. There is a M Possibility, anything similar effects in Ruxolitinib with drugs that are potent inhibitors of CYP3A4. 72 is administered, 73 safety in clinical studies in healthy volunteers and in patients with MF, myelosuppression, particularly thrombocytopenia was the dose-limiting toxicity t the Ruxolitinib. The maximum tolerated dose was 25 mg twice as t Resembled and 100 mg once daily.68, 74 healthy volunteers Ruxolitinib a 50 mg / Neutropenia has developed high grade and recovered 12 days after Ruxolitinib discontinuation.68 established in Phase I / II and III of clinical trials in patients with MF were the h most common h dermatological side effects and thrombocytopenia anemia.74 78 Myelosuppression was dose- dependent and was not an hour withdrawal.74 76 base more often dose-dependent-dependent myelosuppression, in a study of health volunteers. 68 embroidered In the blinded phase III trial strips placebo was observed, reported the h most common non-h h dermatological adverse events more frequently than placebo in the treatment Ruxolitinib were bruising, dizziness and fatigue. Given the mechanism of action of Ruxolitinib, immunosuppression, an adverse event sq.m be possible, but this is not a significant degree been observed in clinical trials to date. In a phase I / II clinical studies researchers have described the symptoms Clinical signs and my development of a systemic inflammatory response syndrome in two patients after a pl Tzlichen ruxolitinib.74 not stopping one Similar reaction has been reported in patients in two Phase III clinical trials.